The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Epidemiology of primary Merkel cell carcinoma in the United States
Agelli, M., & Clegg, L. X. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)02108-x · Cited by 568
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
Miller, R. L., Gerster, J. F., Owens, M. L., Slade, H. B., & Tomai, M. A. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00068-x · Cited by 417
Self-citationGibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkeld, A., & Owens, M. L. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70261-6 · Cited by 363
Self-citationMarks, R., Gebauer, K., Shumack, S., Amies, M., Bryden, J., Fox, T. L., & Owens, M. L. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.113689 · Cited by 333
Self-citationGeisse, J. K., Rich, P., Pandya, A., Gross, K., Andres, K., Ginkel, A., & Owens, M. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.126215 · Cited by 281
Self-citationShumack, S. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.9.1165 · Cited by 236
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Guidelines for the management of basal cell carcinoma
Telfer, N. R., Colver, G. B., & Morton, C. A. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08666.x · Cited by 960
Madan, V., Lear, J. T., & Szeimies, R.-M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61196-x · Cited by 884
Assembly and localization of Toll-like receptor signalling complexes
Gay, N. J., Symmons, M. F., Gangloff, M., & Bryant, C. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3713 · Cited by 832
Rubin, A. I., Chen, E. H., & Ratner, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044151 · Cited by 769
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Guidelines of care for the management of basal cell carcinoma
Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.006 · Cited by 499
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Interventions for basal cell carcinoma of the skin
Bath-Hextall, F. J., Perkins, W., Bong, J., & Williams, H. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003412.pub2 · Cited by 357
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Arits, A. H., Mosterd, K., Essers, B. A., Spoorenberg, E., Sommer, A., De Rooij, M. J., van Pelt, H. P., Quaedvlieg, P. J., Krekels, G. A., van Neer, P. A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70143-8 · Cited by 312
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
TLR7 and TLR8 as targets in cancer therapy
Schön, M. P., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 296
Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review
Love, W. E., Bernhard, J. D., & Bordeaux, J. S. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.291 · Cited by 287
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Berg, D., Bowen, G. M., Cheney, R. T., Daniels, G. A., Glass, L. F., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0065 · Cited by 275
Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells
Chaperot, L., Blum, A., Manches, O., Lui, G., Angel, J., Molens, J.-P., & Plumas, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.248 · Cited by 256
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205
Metadata
- Authors
- Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 50
- Issue
- 5
- Pages
- 722-733
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2054947389
- Cited by
- 505
- References
- 11
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.